Research ArticleArticle
Association of Plasma Concentration of 4β-Hydroxycholesterol with CYP3A5 Polymorphism and Plasma Concentration of Indoxyl Sulfate in Stable Kidney Transplant Recipients
Yosuke Suzuki, Hiroki Itoh, Takashi Fujioka, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata and Satoshi Kishino
Drug Metabolism and Disposition January 2014, 42 (1) 105-110; DOI: https://doi.org/10.1124/dmd.113.054171
Yosuke Suzuki
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Hiroki Itoh
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Takashi Fujioka
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Fuminori Sato
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Kanako Kawasaki
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Yukie Sato
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Yuhki Sato
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Keiko Ohno
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Hiromitsu Mimata
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
Satoshi Kishino
Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita, Japan (Y.S., H.I., T.F., K.K., Y.S., Y.S.); Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita, Japan (F.S., H.M.); and Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan (K.O., S.K.).
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
4β-OHC Depends on CYP3A5 Polymorphism and 3-INDS
Yosuke Suzuki, Hiroki Itoh, Takashi Fujioka, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata and Satoshi Kishino
Drug Metabolism and Disposition January 1, 2014, 42 (1) 105-110; DOI: https://doi.org/10.1124/dmd.113.054171
Research ArticleArticle
4β-OHC Depends on CYP3A5 Polymorphism and 3-INDS
Yosuke Suzuki, Hiroki Itoh, Takashi Fujioka, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata and Satoshi Kishino
Drug Metabolism and Disposition January 1, 2014, 42 (1) 105-110; DOI: https://doi.org/10.1124/dmd.113.054171
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement